STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (fg-203)	TEBIPENEM PIVOXIL HYDROBROMIDE
PRONUNCIATION	teb” i pen’ em piv ox’ il hye” droe broe’ mide
THERAPEUTIC CLAIM	Treatment of severe infections

CHEMICAL NAMES

1. 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, hydrobromide (1:1), (4*R*,5*S*,6*S*)-

2. [(2,2-dimethylpropanoyl)oxy]methyl (4*R*,5*S*,6*S*)-3-{[1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate monohydrobromide

STRUCTURAL FORMULA



MOLECULAR FORMULA	$C_{22}H_{31}N_3O_6S_2$. HBr
MOLECULAR WEIGHT	578.5
TRADEMARK	None
SPONSOR	Spero Therapeutics, Inc.
CODE DESIGNATIONS	TBPM-PI-HBr, SPR994
CAS REGISTRY NUMBER	1381788-20-0
UNII	NT65DX774J

gbk